DI-82 is a potent deoxycytidine kinase (dCK) inhibitor with an IC50app of 27.8 nM and Kiapp of 9.2 nM. DI-82 has antitumor activity[1].
DI-82 (compound 12R) has an IC50 of 3.7 nM in CCRF-CEM acute lymphoblastic leukemia cells[1].
DI-82 (1 μM) has a NADPH-dependent CLint of 22.7 μL/min•mg and a NADPH-dependent T1/2 of 102 mins in a standard microsomal liver clearance assay[1].
DI-82 (200 μM) completely blunts the ability of decitabine to bind human thymidylate synthase (TS)[2].
[1]. Julian Nomme, et al. Structure-guided Development of Deoxycytidine Kinase Inhibitors With Nanomolar Affinity and Improved Metabolic Stability. J Med Chem. 2014 Nov 26;57(22):9480-94.
[2]. Helena Almqvist, et al. CETSA Screening Identifies Known and Novel Thymidylate Synthase Inhibitors and Slow Intracellular Activation of 5-fluorouracil. Nat Commun. 2016 Mar 24;7:11040.